Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial

BACKGROUND: In patients with chronic hepatitis C virus (HCV) genotype 2 or 3, 24 weeks' treatment with pegylated interferon alfa (PEG-IFN-alpha) and ribavirin induces a sustained virological response (SVR) in almost 80% of cases. Evidence suggests that a similar response rate may be obtained wi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Mecenate, Fabrizio, Pellicelli, Adriano M, Barbaro, Giuseppe, Romano, Mario, Barlattani, Angelo, Mazzoni, Ettore, Bonaventura, Maria Elena, Nosotti, Lorenzo, Arcuri, Pasquale, Picardi, Antonio, Barbarini, Giorgio, D'Ambrosio, Cecilia, Paffetti, Amerigo, Andreoli, Arnaldo, Soccorsi, Fabrizio
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2010
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2837223/
https://ncbi.nlm.nih.gov/pubmed/20170514
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-230X-10-21
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller